To test this, we performed both genetic and pharmacological disruption of the mitochondria in a mouse model of Li-Fraumeni Syndrome (LFS), a cancer predisposition disorder characterized by germline mutations in TP53 that can enhance mitochondrial metabolism [6, 7]. Here, TP53 is linked to Li-Fraumeni syndrome.